Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™
 

Spada brings over a decade of specialized trace detection expertise to accelerate the deployment of mass spectrometry technology across global security markets

 

AUSTIN, Texas, January 21, 2026 — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that its subsidiary, 1st Detect Corporation (“1st Detect”), has appointed industry veteran, David Spada, as Director of Global Sales. This strategic hire strengthens 1st Detect's commercial leadership as the company scales deployment of its TRACER 1000™ mass spectrometry-based explosives and narcotics trace detector across international security markets.

Mr. Spada brings over a decade of specialized trace detection experience to the 1st Detect team. Throughout his career at Implant Sciences, Morpho Detection, and Rapiscan Systems, Mr. Spada has held positions of increasing responsibility in product management, strategy, and business development. He was instrumental in commercializing several of the industry’s highest-grossing global trace detectors and was previously accountable for trace detection sales revenue and strategy for the Americas, while supporting broader global sales initiatives.

“David brings extensive industry experience and market knowledge to the 1st Detect team, having been at the forefront of new technology adoption throughout his career,” said Thomas B. Pickens III, Chairman and CEO of Astrotech and 1st Detect. “Trace detection based on mass spectrometry technology has matured into a proven capability, and we believe we have a strong solution with our TRACER 1000 ETD. I look forward to working alongside David to establish our technology as the new standard in security screening.”

The TRACER 1000 uses mass spectrometry to deliver laboratory-grade trace detection in field-deployable systems. By providing accurate molecular identification of threat substances, the technology helps security teams reduce false alarms and strengthen screening checkpoints—an important capability as global security agencies look to modernize their technology.

“1st Detect has a disruptive technology with the TRACER 1000,” said Mr. Spada. “I look forward to ushering in a new era of trace detection based on high performance mass spectrometry and helping to increase shareholder value.”
 

About 1st Detect
 

Based in Austin, Texas, 1st Detect develops, manufactures, and sells trace detectors for security and detection markets. A subsidiary of Astrotech Corporation (Nasdaq: ASTC), the company’s TRACER 1000 ETD® and TRACER 1000 NTD™ systems deliver laboratory-grade performance in portable designs built for real-world environments. For more information, visit www.1stdetect.com.
 

About Astrotech Corporation 
 

Astrotech Corporation (Nasdaq: ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:

 

• 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening.

• AgLAB designs process analyzers tailored to the processing of agriculture products.

• Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.

• BreathTech is advancing a breath analysis platform to detect volatile organic compounds (VOCs) associated with infections and critical health conditions.

• EN-SCAN, Inc. delivers portable, ruggedized environmental GC-MS for on-site testing of air, water and soil.

Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com.

 

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include the words “may,” “will,” “plans,” “believes,” “estimates,” “expects,” “intends,” and other similar expressions. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Investor Contact: Matt Kreps, Managing Director Darrow Associates (214) 597-8200 mkreps@darrowir.com